Generic name:belantamab mafodotin [ bel-AN-ta-mab-MA-foe-DOE-tin ]
Drug class:Miscellaneous antineoplastics
What is Blenrep?
Blenrep is an antibody targeting B-cell maturation antigens (BCMA).
Blenrep is used to treat multiple myeloma in adults. This medicine is given after at least 4 other treatments did not work or have stopped working.
Blenrep was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
Blenrep is available only under a special program. You must be registered in the program and understand the risks and benefits of this medicine.
Warnings
An eye doctor will need to examine your eyes before each dose of this medicine. Blenrep can cause changes to the surface of your eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and an ulcer on the surface of your eye. Tell your healthcare provider if you have any vision changes or eye problems during your treatment.
Even if your vision seems fine, it is important that you get your eyes checked during treatment with Blenrep because some changes can happen without symptoms and may only be seen on an eye exam.
You should use preservative-free lubricant eye drops at least 4 times per day during treatment with Blenrep as instructed by your healthcare provider. You should use caution when driving or operating machinery as this medicine may affect your vision.
Avoid wearing contact lenses during treatment with Blenrep unless directed by your eye specialist.
Before taking this medicine
To make sure Blenrep is safe for you, tell your doctor if you have ever had::
problems with your eyes;
vision problems; or
